Impact of Recombinant Human Growth Hormone on HIV Persistence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03091374

Recruitment Status : Active, not recruiting

First Posted : March 27, 2017

Last Update Posted : March 15, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

EMD Serono

Information provided by (Responsible Party):

Jean-Pierre Routy, McGill University Health Centre/Research Institute of the McGill University Health Centre

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	March 2021
Estimated Study Completion Date :	December 2023

Publications:

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009 Aug;15(8):893-900. doi: 10.1038/nm.1972. Epub 2009 Jun 21.

To Top